Though the NF-κB signaling inhibitor bortezomib, a proteosome inhibitor, has been approved for treatment of multiple myeloma in patients who have failed two prior lines of therapy [67], there have not been many other successful uses of these inhibitors. This evidence concerns the gene NFKB1 and plasma cell myeloma.